Eighteen years ago Interface Biologics Inc. was founded to commercialize a surface modification technology developed by the Santerre lab, with the promise of mitigating thrombosis and infection. This technology is now being acquired by the global chemical manufacturer, Evonik. Read more here.
Evonik acquires division of Santerre Lab spinoff company, Interface Biologics Inc.